Antibacterial and antimycobacterial treatment for inflammatory bowel disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 20, Issue 3, 2005, Pages 340-351

  Ohkusa, Toshifumi ^a   Sato, Nobuhiro ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antibacterial therapy; Antimycobacterial therapy; Crohn's disease; Inflammatory bowel disease; Intestinal bacteria; Ulcerative colitis

Indexed keywords

ANTIBIOTIC AGENT; ANTIMYCOBACTERIAL AGENT; AZATHIOPRINE; AZITHROMYCIN; BETAMETHASONE; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; COTRIMOXAZOLE; DAPSONE; ETHAMBUTOL; HYDROCORTISONE; ISONIAZID; MESALAZINE; METHYLPREDNISOLONE; METRONIDAZOLE; OLSALAZINE; PLACEBO; PREDNISOLONE; PYRIMETHAMINE; RIFABUTIN; RIFAMPICIN; RIFAXIMIN; SALAZOSULFAPYRIDINE; STEROID; SULFADOXINE; TETRACYCLINE; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ADJUVANT THERAPY; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; COLON RESECTION; CONTROLLED STUDY; CROHN DISEASE; DISEASE SEVERITY; ENTERITIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INTESTINE FLORA; MAJOR CLINICAL STUDY; MYCOBACTERIOSIS; MYCOBACTERIUM; PRIORITY JOURNAL; REMISSION; REVIEW; TREATMENT INDICATION; ULCERATIVE COLITIS;

EID: 16344370762     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2004.03472.x     Document Type: Review

References (60)

1. Sartor RB. Intestinal microflora in human and experimental inflammatory bowel disease. Curr. Opin. Gastroenterol. 2001; 17: 324-30.
2. Sartor RB. Review article: how relevant to human inflammatory bowel disease are current animal models of intestinal inflammation? Aliment. Pharmacol. Ther. 1997; 11 (Suppl. 3): 89-96.
3. Sartor RB. Review article: role of the enteric microflora in the pathogenesis of intestinal inflammation and arthritis. Aliment. Pharmacol. Ther. 1997; 11 (Suppl. 3): 17-22.
4. Rath HC, Herfarth HH, Ikeda JS et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta 2 microglobulin transgenic rats. J. Clin. Invest. 1996; 98: 945-53.
5. Robert A, Asano T. Resistance of germfree rats to indomethacin-induced intestinal lesions. Prostaglandins 1977; 14: 333-41.
6. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J. Immunol. 1998; 161: 5733-44.
7. Sadlack B, Merz H, Schorle H et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993; 75: 253-61.
8. Sellon RK, Tonkonogy S, Schultz M et al. Resident enteric flora are necessary for development of spontaneous colitis and immune system activation in IL-10-deficient mice. Infect. Immun. 1998; 66: 5224-31.
9. Dianda L, Hanby AM, Wright NA et al. T cell receptor-αβ- deficient mice fail to develop colitis in the absence of a microbial environment. Am. J. Pathol. 1997; 150: 91-7.
10. Ogura Y, Bonen DK, Inohara N et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603-6.
11. Agnese DM, Calvano JE, Hahm SJ et al. Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J. Infect. Dis. 2002; 186: 1522-5.
12. Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974; 1: 1067-70.
13. Dickinson RJ, O'Connor HJ, Finder I, Hamilton I, Johnston D, Axon AT. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut 1985; 26: 1380-4.
14. Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 1986; 27: 1210-12.
15. Burke DA, Axon AT, Clayden SA, Dixon MF, Johnston D, Lacey RW. The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment. Pharmacol. Ther. 1990; 4: 123-9.
16. Lobo AJ, Burke DA, Sobala GM, Axon AT. Oral tobramycin in ulcerative colitis: effect on maintenance of remission. Aliment. Pharmacol. Ther. 1993; 7: 155-8.
17. Mantzaris GJ, Hatzis A, Kontogiannis P, Triadaphyllou G. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am. J. Gastroenterol. 1994; 89: 43-6.
18. Mantzaris GJ, Archavlis E, Christoforidis P et al. A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. Am. J. Gastroenterol. 1997; 92: 454-6.
19. Turunen UM, Farkkila MA, Hakala K et al. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology 1998; 115: 1072-8.
20. Gionchetti P, Rizzello F, Ferrieri A et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig. Dis. Sci. 1999; 44: 1220-1.
21. Matsuda H, Fujiyama Y, Andoh A, Ushijima T, Kajinami T, Bamba T. Characterization of antibody responses against rectal mucosa-associated bacterial flora in patients with ulcerative colitis. J. Gastroenterol. Hepatol. 2000; 15: 61-8.
22. Ohkusa T, Sato N, Ogihara T, Morita K, Ogawa M, Okayasu I. Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J. Gastroenterol. Hepatol. 2002; 17: 849-53.
23. Ohkusa T, Okayasu I, Ogihara T, Morita K, Ogawa M, Sato N. Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut 2003; 52: 79-83.
24. Ursing B, Kamme C. Metronidazole for Crohn's disease. Lancet 1975; 1: 775-7.
25. Holdstock DJ. Drug treatment in Crohn's disease. [Letter] Lancet 1975; 2: 1260.
26. Blichfeldt P, Blomhoff JP, Myhre E, Gjone E. Metronidazole in Crohn's disease. A double blind crossover clinical trial. Scand. J. Gastroenterol. 1978; 13: 123-7.
27. Ursing B, Alm T, Barany F et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology 1982; 83: 550-62.
28. Ambrose NS, Allan RN, Keighley MR et al. Antibiotic therapy for treatment in relapse of intestinal Crohn's disease. A prospective randomized study. Dis. Colon Rectum 1985; 28: 81-5.
29. Sutherland L, Singleton J, Sessions J et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991; 32: 1071-5.
30. Rutgeerts P, Hiele M, Geboes K et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995; 108: 1617-21.
31. Brandt LJ, Bernstein LH, Boley SJ, Frank MS. Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology 1982; 83: 383-7.
32. Jakobovits J, Schuster MM. Metronidazole therapy for Crohn's disease and associated fistulae. Am. J. Gastroenterol. 1984; 79: 533-40.
33. Duffy LF, Daum F, Fisher SE et al. Peripheral neuropathy in Crohn's disease patients treated with metronidazole. Gastroenterology 1985; 88: 681-4.
34. Roe FJ. Toxicologic evaluation of metronidazole with particular reference to carcinogenic, mutagenic, and teratogenic potential. Surgery 1983; 93: 158-64.
35. Beard CM, Noller KL, O'Fallon WM, Kurland LT, Dockerty MB. Lack of evidence for cancer due to use of metronidazole. N. Engl. J. Med. 1979; 301: 519-22.
36. Peppercorn MA. Is there a role for antibiotics as primary therapy in Crohn's ileitis? J. Clin. Gastroenterol. 1993; 17: 235-7.
37. Prantera C, Kohn A, Zannoni F, Spimpolo N, Bonfa M. Metronidazole plus ciprofloxacin in the treatment of active, refractory Crohn's disease: results of an open study. J. Clin. Gastroenterol. 1994; 19: 79-80.
38. Prantera C, Zannoni F, Scribano ML et al. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am. J. Gastroenterol. 1996; 91: 328-32.
39. Greenbloom SL, Steinhart AH, Greenberg GR. Combination ciprofloxacin and metronidazole for active Crohn's disease. Can. J. Gastroenterol. 1998; 12: 53-6.
40. Colombel JF, Lemann M, Cassagnou M et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Am. J. Gastroenterol. 1999; 94: 674-8.
41. Dalziel TK. Chronic intestinal enteritis. Br. Med. J. 1913; 2: 1068-70.
42. Burnham WR, Lennard-Jones JE, Stanford JL, Bird RG. Mycobacteria as a possible cause of inflammatory bowel disease. Lancet 1978; 2: 693-6.
43. Chiodini RJ, Van Kruiningen HJ, Thayer WR, Merkal RS, Coutu JA. Possible role of mycobacteria in inflammatory bowel disease. I. An unclassified mycobacterium species isolated from patients with Crohn's disease. Dig. Dis. Sci. 1984; 29: 1073-9.
44. Chiodini RJ. Crohn's disease and the mycobacterioses: a review and comparison of two disease entities. Clin. Microbiol. Rev. 1989; 2: 90-117.
45. Elliott PR, Burnham WR, Berghouse LM, Lennard-Jones JE, Langman MJ. Sulphadoxine-pyrimethamine therapy in Crohn's disease. Digestion 1982; 23: 132-4.
46. Shaffer JL, Hughes S, Linaker BD, Baker RD, Turnberg LA. Controlled trial of rifampicin and ethambutol in Crohn's disease. Gut 1984; 25: 203-5.
47. Basilisco G, Ranzi T, Campanini MC, Piodi L, Bianchi A. Controlled trial of rifabutin in Crohn's disease. Curr. Ther. Res. 1989; 46: 245-50.
48. Afdhal NH, Long A, Lennon J, Crowe J, O'Donoghue DP. Controlled trial of antimycobacterial therapy in Crohn's disease. Clofazimine versus placebo. Dig. Dis. Sci. 1991; 36: 449-53.
49. Prantera C, Kohn A, Mangiarotti R, Andreoli A, Luzi C. Antimycobacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. Am. J. Gastroenterol. 1994; 89: 513-18.
50. Swift GL, Srivastava ED, Stone R et al. Controlled trial of anti-tuberculous chemotherapy for 2 years in Crohn's disease. Gut 1994; 35: 363-8.
51. Kelleher D, O'Brien S, Weir DG. Preliminary trial of clofazimine in chronic inflammatory bowel disease. Gut 1982; 23: A449 [Abstract].
52. Graham DY, Al-Assi MT, Robinson M. Prolonged remission in Crohn's disease following therapy for Mycobacterium paratuberculosis infection. Gastroenterology 1995; 108: A826 [Abstract].
53. Goodgame RW, Kimball K, Akram S, Graham DY, Ou C. Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. Gastroenterology 1999; 116: A725 [Abstract].
54. Rastogi N, Goh KS, Labrousse V. Activity of clarithromycin compared with those of other drugs against Mycobacterium paratuberculosis and further enhancement of its extracellular and intracellular activities by ethambutol. Antimicrob. Agents Chemother. 1992; 36: 2843-6.
55. Raleigh J. Chemotherapy of tuberculosis. In: Kubica G, Wayne L, eds. Mycobacteria: A Source Book, Vol. 15. New York: Marcel Dekker, 1984; 1007-20.
56. Mor N, Vanderkolk J, Mezo N, Heifets L. Effects of clarithromycin and rifabutin alone and in combination on intracellular and extracellular replication of Mycobacterium avium. Antimicrob. Agents Chemother. 1994; 38: 2738-42.
57. Gui GP, Thomas PR, Tizard ML, Lake J, Sanderson JD, Hermon-Taylor J. Two-year outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. J. Antimicrob. Chemother. 1997; 39: 393-400.
58. Douglass A, Cann PA, Bramble MG. An open pilot study of antimicrobial therapy in patients with unresponsive Crohn's disease. Gut 2000; 46 (Suppl. II): A11 [Abstract].
59. Shafran I, Kugler L, El-Zaatari FA, Naser SA, Sandoval J. Open clinical trial of rifabutin and clarithromycin therapy in Crohn's disease. Dig. Liver Dis. 2002; 34: 22-8.
60. Borody TJ, Leis S, Warren EF, Surace R. Treatment of severe Crohn's disease using antimycobacterial triple therapy-approaching a cure? Dig. Liver Dis. 2002; 34: 29-38.